O'Loughlin S, Goldman G C, Provost T T
Arch Dermatol. 1978 Dec;114(12):1769-72.
Six of 17 pemphigus patients (35%) treated during a six-year period with immunosuppressive agents and/or corticosteroids have had prolonged clinical and immunologic remissions off all therapy. All were treated until serum and tissue bound pemphigus antibodies could no longer be detected. The length of remission has ranged from 1 1/2 years to 4 years. Three of these six patients relapsed after being clinically and serologically free of pemphigus for 19, 20, and 48 months. Seven additional patients are clinically free of disease with insignificant pemphigus antibody titers of 10 or less. Therapy now is being discontinued gradually in these patients. This preliminary study demonstrates that (1) a large percentage of pemphigus patients may have a prolonged clinical and immunological remission after successful therapy; (2) maintenance therapy may not be required to preserve the remission; (3) monitoring serum and in vivo bound pemphigus antibody is of value in regulating therapy in pemphigus patients.
在六年期间，17例接受免疫抑制剂和/或皮质类固醇治疗的天疱疮患者中有6例（35%）在停止所有治疗后获得了长期的临床和免疫缓解。所有患者均接受治疗，直至血清和组织中结合的天疱疮抗体无法再被检测到。缓解期从1.5年到4年不等。这6例患者中有3例在临床和血清学上无天疱疮表现19、20和48个月后复发。另外7例患者临床上无疾病表现，天疱疮抗体滴度为10或更低，不显著。目前正在逐渐停止对这些患者的治疗。这项初步研究表明：（1）很大一部分天疱疮患者在成功治疗后可能获得长期的临床和免疫缓解；（2）可能不需要维持治疗来维持缓解；（3）监测血清和体内结合的天疱疮抗体对调节天疱疮患者的治疗有价值。
